Saturday, October 3, 2026

USD/CNH Bearish Momentum With A 1% Drop In The Last 10 Sessions

ViaNews Editorial Team

February 13, 2024

USD/CNH Bearish Momentum With A 1% Drop In The Last 10 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 1.54% for the last 10 sessions. At 04:13 EST on Tuesday, 13 February, USD/CNH (USDCNH) is $7.22.

USD/CNH's yearly highs and lows, it's 0.065% up from its 52-week low and 0.079% down from its 52-week high.

News about

  • According to FXStreet on Monday, 12 February, "This further contributes to the USD/JPY pair's subdued range-bound price action during the Asian session on Monday. ", "The latter should act as a key pivotal point, which if broken decisively could drag the USD/JPY pair to the 147.00 mark en route to the 146.35 region and the monthly swing low, around the 145.90 zone."
  • Usd/jpy flatlines above 149.30, investors await US CPI data. According to FXStreet on Tuesday, 13 February, "The USD/JPY pair trades on a flat note during the early Asian session on Tuesday. "
  • Usd/jpy analysis: yen selling pressure renewed - 12 February 2024. According to DailyForex on Monday, 12 February, "In the long term, and according to the performance on the daily chart, USD/JPY appears to trade within an upward channel. ", "The price of the USD/JPY pair has now advanced to trade at a few levels above the 100-hour moving average line. "
  • Usd/jpy signal: continues to look bullish overall - 12 February 2024. According to DailyForex on Monday, 12 February, "Support levels for the USD/JPY pair are identified at 147.50, 147.33, and reinforced by the 50-day Exponential Moving Average (EMA). ", "In the USD/JPY market, the dollar initially experienced a decline against the yen on Friday, but indications suggest a reversal to resume upward momentum. "

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com